Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.

[1]  E. Schaeffner,et al.  Cystatin C-Based Equation to Estimate GFR without the Inclusion of Race and Sex. , 2023, The New England journal of medicine.

[2]  A. Krishnan,et al.  Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. , 2022, The New England journal of medicine.

[3]  M. Drayson,et al.  Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial , 2022, Blood Cancer Journal.

[4]  Yaeni Kim,et al.  Response and dynamics of renal function for transplant-eligible multiple myeloma patients who were treated with novel agent: The CAREMM-2201 study. , 2022, Transplantation and cellular therapy.

[5]  P. Maciag,et al.  Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma , 2022, British journal of clinical pharmacology.

[6]  S. Lonial,et al.  P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial , 2022, Clinical Lymphoma, Myeloma & Leukemia.

[7]  A. Krishnan,et al.  Teclistamab in Relapsed or Refractory Multiple Myeloma. , 2022, The New England journal of medicine.

[8]  C. Sordo-Bahamonde,et al.  Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma , 2022, Advances in hematology.

[9]  H. Einsele,et al.  Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors , 2022, American journal of hematology.

[10]  D. Lad,et al.  Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment. , 2022, Clinical lymphoma, myeloma & leukemia.

[11]  M. Dimopoulos,et al.  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. , 2022, The Lancet. Oncology.

[12]  M. Dimopoulos,et al.  Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study , 2021, American journal of hematology.

[13]  H. Goldschmidt,et al.  Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose , 2021, Blood.

[14]  Shaji K. Kumar,et al.  Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. , 2021, Transplantation and cellular therapy.

[15]  N. Powe,et al.  A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Trevor J Pugh,et al.  Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration , 2021, Clinical Cancer Research.

[17]  S. Jagannath,et al.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.

[18]  M. Arcila,et al.  Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. , 2021, The Lancet. Haematology.

[19]  Chunrui Li,et al.  Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function , 2021, Current Medical Science.

[20]  M. Dimopoulos,et al.  Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[21]  He Huang,et al.  Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019 , 2021, BMC Cancer.

[22]  D. Hose,et al.  Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial , 2021, Leukemia.

[23]  Toshiki Terao,et al.  Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure , 2021, British journal of haematology.

[24]  M. Dimopoulos,et al.  Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. , 2021, The Lancet. Oncology.

[25]  H. Einsele,et al.  Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM , 2021, Cancers.

[26]  H. Goldschmidt,et al.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.

[27]  H. Goldschmidt,et al.  Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up , 2021, HemaSphere.

[28]  S. Jagannath,et al.  Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. , 2021, Blood advances.

[29]  S. Nasr,et al.  Management of acute kidney injury in symptomatic multiple myeloma. , 2021, Kidney international.

[30]  S. Kambhampati,et al.  Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019 , 2021, Leukemia & lymphoma.

[31]  M. Dimopoulos,et al.  A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. , 2020, Blood advances.

[32]  M. Dimopoulos,et al.  Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis , 2020, Haematologica.

[33]  J. Mikhael,et al.  Real-world renal function among patients with multiple myeloma in the United States , 2020, Blood Cancer Journal.

[34]  M. Dimopoulos,et al.  Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients , 2020, Blood Cancer Journal.

[35]  Jianda Hu,et al.  Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients , 2020, Journal of clinical laboratory analysis.

[36]  S. Sanada,et al.  Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen , 2020, International Journal of Hematology.

[37]  M. Dimopoulos,et al.  Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study , 2020, The Lancet.

[38]  B. Pégourié,et al.  Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Lonial,et al.  Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. , 2020, The Lancet. Haematology.

[40]  S. Lonial,et al.  DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. , 2020 .

[41]  M. Dimopoulos,et al.  Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis , 2020, Leukemia.

[42]  M. Dimopoulos,et al.  Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM. , 2020 .

[43]  Junnian Zheng,et al.  Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment , 2020, Bone Marrow Transplantation.

[44]  A. Pani,et al.  Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: A multicenter retrospective study. , 2020, Blood.

[45]  E. Brown,et al.  Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study , 2020, Blood Cancer Journal.

[46]  P. Jeyaraman,et al.  Daratumumab in dialysis-dependent multiple myeloma , 2020, Blood research.

[47]  M. Dimopoulos,et al.  Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis , 2020, Blood Cancer Journal.

[48]  P. Aljama,et al.  Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients , 2020, BMC Nephrology.

[49]  M. Dimopoulos,et al.  Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study , 2020, Leukemia.

[50]  M. Ruiz,et al.  Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study , 2019, British journal of haematology.

[51]  R. Pearse,et al.  Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution , 2019, Blood.

[52]  J. Shah,et al.  Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study , 2019, Clinical Lymphoma, Myeloma & Leukemia.

[53]  S. Trudel,et al.  Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras , 2019, Bone Marrow Transplantation.

[54]  C. Reid,et al.  Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. , 2019, Clinical lymphoma, myeloma & leukemia.

[55]  R. Sahoo,et al.  Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma , 2019, Clinical hematology international.

[56]  P. Conlon,et al.  Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure , 2019, Irish Journal of Medical Science (1971 -).

[57]  P. Sonneveld,et al.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.

[58]  M. Beksac,et al.  Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[59]  N. Heyne,et al.  High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. , 2019, The Lancet. Haematology.

[60]  M. Macía,et al.  Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias: Case Reports. , 2019, Transplantation proceedings.

[61]  R. Benjamin,et al.  Risk of relapse of multiple myeloma following kidney transplantation , 2019, Clinical kidney journal.

[62]  M. Dimopoulos,et al.  Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. , 2019, Blood.

[63]  V. D’Agati,et al.  The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group , 2018, Nature Reviews Nephrology.

[64]  Michael D. Robbins,et al.  Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma , 2018, The New England journal of medicine.

[65]  H. Gisslinger,et al.  Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study , 2018, BMC Cancer.

[66]  J. Manola,et al.  Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study , 2018, Blood Cancer Journal.

[67]  E. V. van Roon,et al.  The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study , 2018, Haematologica.

[68]  A. Jakubowiak,et al.  Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). , 2018 .

[69]  J. Bladé,et al.  Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  E. Zamagni,et al.  Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma , 2018, Haematologica.

[71]  I. Yakoub-Agha,et al.  Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC , 2018, Bone Marrow Transplantation.

[72]  M. Dimopoulos,et al.  Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  H. Goldschmidt,et al.  Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  P. Richardson,et al.  CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.

[75]  B. Pégourié,et al.  Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial , 2017, JAMA.

[76]  M. Dimopoulos,et al.  Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function , 2017, Clinical pharmacology : advances and applications.

[77]  P. Hari,et al.  The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. , 2017, Journal of geriatric oncology.

[78]  K. Venkatakrishnan,et al.  A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors , 2017, Investigational New Drugs.

[79]  G. Bongartz,et al.  Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines , 2017, European Radiology.

[80]  O. Decaux,et al.  Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury , 2017, Clinical kidney journal.

[81]  G. Danovitch,et al.  Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports , 2017, Transplantation direct.

[82]  A. Krishnan,et al.  Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A Center for International Blood and Marrow Transplant Research Analysis , 2017, Bone Marrow Transplantation.

[83]  M. Dimopoulos,et al.  Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit , 2017, Blood Cancer Journal.

[84]  C. Peralta,et al.  Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[85]  M. Dimopoulos,et al.  Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study , 2017, British journal of haematology.

[86]  Y. Ou,et al.  Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study , 2017, Cancer Chemotherapy and Pharmacology.

[87]  M. van Meurs,et al.  Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria , 2017, BMC Nephrology.

[88]  R. Benjamin,et al.  Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience , 2017, British journal of haematology.

[89]  Wenming Chen,et al.  Bortezomib-based treatment for multiple myeloma patients with renal impairment , 2016, Medicine.

[90]  A. Santoro,et al.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology , 2016, Journal of Nephrology.

[91]  H. Goldschmidt,et al.  International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[93]  Y. Tomonaga,et al.  Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy , 2016, PloS one.

[94]  H. Goldschmidt,et al.  Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma , 2016, Haematologica.

[95]  M. Dimopoulos,et al.  A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) , 2016, Leukemia.

[96]  H. Goldschmidt,et al.  Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials , 2016, Leukemia & lymphoma.

[97]  Huyuan Yang,et al.  A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis , 2016, British journal of haematology.

[98]  H. Gerth,et al.  Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study , 2016, PloS one.

[99]  M. Dimopoulos,et al.  Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis , 2016, American journal of hematology.

[100]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[101]  S. Jagannath,et al.  Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study , 2015, Clinical lymphoma, myeloma & leukemia.

[102]  S. Jagannath,et al.  Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. , 2015, The Lancet. Haematology.

[103]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[104]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[106]  E. Mancini,et al.  Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment , 2015, American journal of hematology.

[107]  Xiaohong Chen,et al.  Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. , 2015, International journal of clinical pharmacology and therapeutics.

[108]  G. Palladino,et al.  A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR) , 2015, Journal of Nephrology.

[109]  Z. Cai,et al.  Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment , 2015, International Journal of Hematology.

[110]  R. Greil,et al.  Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study , 2015, Haematologica.

[111]  D. Esseltine,et al.  Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study , 2015, Haematologica.

[112]  D. Dingli,et al.  Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma , 2014, Blood Cancer Journal.

[113]  L. Buie,et al.  Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. , 2014, Clinical lymphoma, myeloma & leukemia.

[114]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[115]  A. Foli,et al.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.

[116]  G. Gahrton,et al.  The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment , 2014, PloS one.

[117]  N. Chen,et al.  Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: a 15-year retrospective, single center, cohort study , 2014, Leukemia & lymphoma.

[118]  M. Kersten,et al.  Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial , 2014, Haematologica.

[119]  D. Niederwieser,et al.  Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure , 2013, Journal of Cancer Research and Clinical Oncology.

[120]  M. Dimopoulos,et al.  The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma , 2013, Leukemia.

[121]  R. Vij,et al.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety , 2013, Leukemia.

[122]  J. Kosek,et al.  Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration , 2012, Cancer Chemotherapy and Pharmacology.

[123]  S. Cha,et al.  Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[124]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[125]  M. Goldman,et al.  Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy , 2012, Hematology.

[126]  H. Goldschmidt,et al.  Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment , 2011, Annals of Hematology.

[127]  D. Seldin,et al.  Kidney dysfunction during lenalidomide treatment for AL amyloidosis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[128]  D. Pereira,et al.  High‐dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma , 2011, American journal of hematology.

[129]  B. Barlogie,et al.  Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  R. Greil,et al.  Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  M. Sanz,et al.  Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study , 2010, European journal of haematology.

[132]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[133]  M. Dimopoulos,et al.  Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment , 2010, European journal of haematology.

[134]  F. Dekker,et al.  Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[135]  H. Goldschmidt,et al.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function , 2010, Cancer.

[136]  F. Dekker,et al.  Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[137]  K. Tsuchiya,et al.  A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT , 2010, Bone Marrow Transplantation.

[138]  M. Dimopoulos,et al.  VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  M. Dimopoulos,et al.  Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. , 2009, Clinical lymphoma & myeloma.

[140]  Michael L. Wang,et al.  Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[141]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[142]  P. Sonneveld,et al.  Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. , 2008, Clinical lymphoma & myeloma.

[143]  R. Neuwirth,et al.  Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study , 2008, Leukemia.

[144]  O. Laskin,et al.  Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis , 2007, Journal of clinical pharmacology.

[145]  M. Dimopoulos,et al.  Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. , 2007, Haematologica.

[146]  T. Economopoulos,et al.  Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance , 2007, Leukemia & lymphoma.

[147]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[148]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  Amit X Garg,et al.  Plasma Exchange When Myeloma Presents as Acute Renal Failure , 2005, Annals of Internal Medicine.

[150]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[151]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[152]  D. Esseltine,et al.  Bortezomib in recurrent and/or refractory multiple myeloma , 2005, Cancer.

[153]  M. Baccarani,et al.  Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure , 2004, European journal of haematology.

[154]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[155]  B. Barlogie,et al.  Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant , 2004, Bone Marrow Transplantation.

[156]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[157]  D. Budman,et al.  The Pharmacokinetics and Pharmacodynamics of Fludarabine Phosphate in Patients with Renal Impairment: A Prospective Dose Adjustment Study , 2002, Cancer investigation.

[158]  L. Agodoa,et al.  Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. , 2001, Clinical nephrology.

[159]  S. Montoto,et al.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. , 1998, Archives of internal medicine.

[160]  R. Kyle,et al.  A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. , 1995, Leukemia.

[161]  P. Sanders,et al.  Pathobiology of cast nephropathy from human Bence Jones proteins. , 1992, The Journal of clinical investigation.

[162]  A. Newland,et al.  One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy. , 1989, Clinical and laboratory haematology.

[163]  Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. , 1984, British medical journal.

[164]  M. Dimopoulos,et al.  Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[165]  H. Goldschmidt,et al.  The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. , 2006, Haematologica.